Boehringer Ingelheim's Open Letter For Pradaxa Brings Australian PBS Back Into Spotlight
This article was originally published in PharmAsia News
Executive Summary
Pharmaceutical giant Boehringer Ingelheim took on the Australian federal government Nov. 2, calling for the approval of Boehringer's new anti-coagulant drug Pradaxa (dabigatran) for the country's Pharmaceutical Benefits Scheme